News
QURE
5.92
+11.07%
0.59
Strength Seen in Dianthus Therapeutics, Inc. (DNTH): Can Its 5.7% Jump Turn into More Strength?
NASDAQ · 14h ago
Weekly Report: what happened at QURE last week (0930-1004)?
Weekly Report · 2d ago
Q3 pharma and biotech layoffs in charts: More than 1000 each in July and August
Seeking Alpha · 5d ago
uniQure (NASDAQ:QURE shareholders incur further losses as stock declines 10% this week, taking five-year losses to 89%
Simply Wall St · 10/02 10:31
Weekly Report: what happened at QURE last week (0923-0927)?
Weekly Report · 09/30 09:10
Centessa Pharmaceuticals: Progressing SerpinPC Through Registrational Trials In Hemophilia B
Seeking Alpha · 09/25 20:38
uniQure Gains FDA Orphan Drug Status for Fabry Disease Therapy
TipRanks · 09/23 11:57
UniQure's Fabry Disease Treatment Gets Orphan Drug Designation from FDA
Dow Jones · 09/23 11:36
FDA Grants Orphan Drug Status to uniQure's AMT-191, Aiming to Treat Fabry Disease
Benzinga · 09/23 11:07
Weekly Report: what happened at QURE last week (0916-0920)?
Weekly Report · 09/23 09:10
uniQure Biopharma Granted Orphan Drug Designation For Its 'adeno-associated Viral Vector Serotype 5 Encoding Human Alpha-galactosidase A' For The Treatment Of Fabry Disease
Benzinga · 09/19 15:54
Weekly Report: what happened at QURE last week (0909-0913)?
Weekly Report · 09/16 09:09
Weekly Report: what happened at QURE last week (0902-0906)?
Weekly Report · 09/09 09:10
Institutional owners may take dramatic actions as uniQure N.V.'s (NASDAQ:QURE) recent 11% drop adds to one-year losses
Simply Wall St · 09/05 10:35
Weekly Report: what happened at QURE last week (0826-0830)?
Weekly Report · 09/02 09:10
Weekly Report: what happened at QURE last week (0819-0823)?
Weekly Report · 08/26 09:10
Buy Rating Affirmed: uniQure’s Promising Gene Therapy Pipeline and Strategic Focus
TipRanks · 08/20 10:51
Weekly Report: what happened at QURE last week (0812-0816)?
Weekly Report · 08/19 09:09
uniQure Begins Phase I/IIa Trial for Fabry Disease Treatment
TipRanks · 08/15 12:22
uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease
Barchart · 08/15 06:05
More
Webull provides a variety of real-time QURE stock news. You can receive the latest news about Uniqure through multiple platforms. This information may help you make smarter investment decisions.
About QURE
Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.